Abstracts tagged "rituximab and ultrasound"

Abstract Number: 2209 • 2018 ACR/ARHP Annual Meeting
Fluorescence Optical Imaging Xiralite® Is Helpful in the Decision for Rituximab Re-Therapy in Patients with Rheumatoid Arthritis
Sarah Ohrndorf¹, Lisa Ridha², Anne-Marie Glimm³, Gerd R. Burmester¹, Gabriela Schmittat³, Marina Backhaus⁴ and Jens Klotsche⁵, ¹Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany, ⁵Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rituximab (RTX) is an effective and well-tolerated therapeutic option in rheumatoid arthritis (RA) patients with insufficient response to TNFα inhibitors. However, the exact time…
Abstract Number: 874 • 2017 ACR/ARHP Annual Meeting
Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sjögren’s Syndrome: Results of Multicentre Double-Blind Randomised Controlled Trial Sub-Study
Benjamin Fisher¹, Colin Everett², John Rout³, John O'Dwyer², Paul Emery⁴, Costantino Pitzalis⁵, Wan-Fai Ng⁶, Andrew Carr⁷, Colin Pease², Elizabeth Price⁸, Nurhan Sutcliffe⁹, Jimmy Makdissi¹⁰, Anwar Tappuni¹⁰, Nagui Gendi¹¹, Frances Hall¹², Sharon Ruddock², Catherine Fernandez², Claire Hulme², Kevin Davies¹³, Christopher J. Edwards¹⁴, Peter Lanyon¹⁵, Robert J. Moots¹⁶, Euthalia Roussou¹⁷, Linda Sharples¹⁸, Michele Bombardieri¹⁹ and Simon Bowman²⁰, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Birmingham Dental Hospital, Birmingham, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁶Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Newcastle Dental Hospital, Newcastle, United Kingdom, ⁸Great Western Hospital, Swindon, United Kingdom, ⁹Royal London Hospital, London, UK, London, United Kingdom, ¹⁰Barts Health NHS Trust, London, United Kingdom, ¹¹Basildon and Thurrock University Hospital, Basildon, UK, Basildon, United Kingdom, ¹²School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ¹³University of Sussex, Brighton, United Kingdom, ¹⁴University of Southampton, Southampton, United Kingdom, ¹⁵University of Nottingham, Nottingham, United Kingdom, ¹⁶University of Liverpool, Liverpool, United Kingdom, ¹⁷Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, ¹⁸London School of Hygiene and Tropical Medicine, London, United Kingdom, ¹⁹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ²⁰Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom
Background/Purpose: B lymphocytes are important in the pathogenesis of primary Sjögren’s syndrome (PSS), but two phase III trials (TEARS and TRACTISS) of the B cell…
Abstract Number: 2519 • 2016 ACR/ARHP Annual Meeting
Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Mediola Ismajli¹ and Maria J. Leandro², ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Title: Predictors of flare in rheumatoid arthritis patients treated preventively with rituximab: a prospective study using ultrasound and patient reported outcomes Background/Purpose: Rituximab (RTX) is…
Abstract Number: 492 • 2015 ACR/ARHP Annual Meeting
Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
Andreea Borangiu¹, Diana Mazilu¹, Ioana Saulescu¹, Evelina Iachim², Laura Grosanu¹, Cosmin Constantinescu¹, Andra Balanescu¹, Denisa Predeteanu¹, Ruxandra Ionescu¹ and Daniela Opris¹, ¹University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Carol Davila Medicine and Pharmacy University, Bucharest, Romania
Background/Purpose: Correct assessment to biologics in rheumatoid arthritis (RA) patients is extremely important regarding future patient management. There is still an open debate about the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].